ClinicaliQ Trial Snapshot
- A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials — Recruiting • Cardiology / Cardiovascular • NCT06285318.
- What is being tested: Real-world clinical outcomes and safety data for two T-cell redirector therapies (teclistamab and talquetamab) in patients with relapsed/refractory multiple myeloma (RRMM) treated in routine clinical practice outside formal trial settings.
- Patient eligibility overview: Adults with RRMM who have received these T-cell redirector therapies in standard care environments; the study captures real-world patient populations rather than those meeting strict trial inclusion/exclusion criteria.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to describe the use of teclistamab/talquetamab in the treatment of patients with RRMM outside of clinical trials.
Eligibility Snapshot
- : * Have a documented diagnosis of multiple myeloma * Received the first dose of teclistamab on or before 31 December 2022, regardless of the duration of teclistamab treatment (REALiTEC cohort 1) OR Received the first dose of teclistamab from 01 January 2023 to 31 December 2024, inclusive, regardless of the duration of teclistamab treatment (REALiTEC cohort 2) OR Received the first dose of teclistamab from 01 January 2025 to 31 December 2025, inclusive, regardless of the duration of teclistamab treatment (REALiTEC cohort 3) OR Received the first dose of talquetamab on or before 31 December 2023, regardless of the duration of talquetamab treatment (REALiTAL cohort). Participants who received both teclistamab & talquetamab can be included in both REALiTEC and REALiTAL cohorts * Received at least one dose of teclistamab/talquetamab * Provision of a patient-signed informed consent form (ICF), or an ICF waiver for deceased patients as applicable based on country/site-specific requirements
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.